论文部分内容阅读
目的:回顾性分析替加环素治疗广泛耐药鲍曼不动杆菌(XDRAB)的微生物学清除率及临床治疗效果。方法:选择我院重症医学科2013~2014年29例确诊为XDRAB感染并单用或联合使用替加环素治疗的患者的病历资料。替加环素首剂100 mg,随后每12 h 50 mg ivd,疗程≥3 d,收集其临床及微生物学相关资料。结果:29例XDRAB感染患者应用替加环素治疗后,11例(37.9%)临床治疗有效,8例(27.6%)微生物清除。10例(34.5%)因临床和细菌学反应差而在2周内死亡。替加环素联合头孢哌酮/舒巴坦的临床有效率75%,优于其他方案。结论:替加环素联合头孢哌酮/舒巴坦治疗XDRAB感染效果较好。
Objective: To retrospectively analyze the microbiological clearance rates and clinical effects of tigecycline in the treatment of Acinetobacter baumannii (XDRAB). Methods: The medical records of 29 patients diagnosed as XDRAB infection and treated with tigecycline alone or in combination with selected patients from 2013 to 2014 in our department of critical care were selected. Tigecycline first dose of 100 mg, then every 12 h 50 mg ivd, treatment ≥ 3d, collect their clinical and microbiological related information. Results: Of the 29 XDRAB-infected patients treated with tigecycline, 11 (37.9%) were clinically effective and 8 (27.6%) were cleared of microbes. Ten patients (34.5%) died within two weeks due to poor clinical and bacteriological reactions. The clinical efficacy of tigecycline plus cefoperazone / sulbactam was 75% better than the other regimens. Conclusion: Tigecycline and cefoperazone / sulbactam are effective in treating XDRAB infection.